Propanc Biopharma Files Fourth Provisional Patent; Expands IP Portfolio To Advance PRP Proenzyme Therapy For Metastatic Cancer

Propanc Biopharma, Inc. (NASDAQ: PPCB) has filed its fourth provisional patent application in two months, expanding its intellectual property portfolio related to its lead asset, PRP proenzyme therapy for metastatic cancer. The new patent focuses on innovative formulations of pancreatic proenzymes aimed at overcoming challenges in stability and transport. CEO James Nathanielsz indicated that the company expects to double its IP portfolio from approximately 90 to over 200 patents, which will support the advancement of PRP into a Phase 1b First-In-Human study. This development positions Propanc to address significant unmet needs in cancer treatment.